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S U M M A R Y
Objectives: To investigate the emergence of NDM-, OXA-48-, and VIM-producing Klebsiella pneumoniae in
Saudi Arabia.
Methods: From June to December 2011, we obtained K. pneumoniae isolates with reduced sensitivity to
carbapenem identiﬁed in Riyadh, Saudi Arabia. Only non-duplicate clinical and surveillance isolates
obtained from inpatients were included. PCR ampliﬁcation was carried out for the detection of extended-
spectrum beta-lactamase genes (blaCTX-M, blaTEM, blaSHV) and carbapenemase genes (blaKPC, blaVIM,
blaIMP, blaNDM, and blaOXA-48). Susceptibility to imipenem, meropenem, amikacin, gentamicin,
trimethoprim–sulfamethoxazole, and colistin was determined.
Results: Of the 60 K. pneumoniae isolates studied, 45 were from patients in the intensive care unit. Forty-
seven isolates harbored blaOXA-48, 12 were positive for blaNDM, and one for blaVIM. No isolate harbored a
combination of these resistance genes. No isolate harbored blaKPC or blaIMP. All 37 blaCTX-M-positive
isolates belonged to CTX-M group 1, and 29 were positive for a combination of blaCTX-M and blaOXA-48.
blaTEM and blaSHV genes were found in 17 and 39 isolates, respectively. All isolates were imipenem- and
meropenem-resistant, with a high rate of co-resistance to the other antibiotics. Three blaOXA-48-positive
isolates with colistin resistance were detected.
Conclusion: Multidrug-resistant K. pneumoniae isolates harboring blaOXA-48, blaNDM, and colistin
resistance are emerging in Saudi Arabia.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Over the last couple of decades, the emergence and rapid
dissemination of extended-spectrum beta-lactamase (ESBL)-pro-
ducing bacteria has led to the increased utilization of carbapenems
in clinical practice. This is largely because ESBL-producers, which
are capable of hydrolyzing penicillins, broad-spectrum cephalos-
porins, and monobactams, also harbor resistance genes for other
antibiotics, thus making carbapenems the last option for the
treatment of serious infections associated with these organisms.1 A
consequence of this increased utilization of carbapenems has been
the emergence of isolates with resistance genes that code for
carbapenemases.2 Among the Enterobacteriaceae, clinically signiﬁ-
cant carbapenemases are the Ambler molecular class A (KPC), class
B (VIM, IMP, NDM), and class D (OXA-48) types.3 These are mostly* Corresponding author. Tel.: +966 5 0530 2775; fax: +966 1 468 3813.
E-mail addresses: amshibl@ksu.edu.sa, amshibl1@yahoo.com (A. Shibl).
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http://dx.doi.org/10.1016/j.ijid.2013.06.016found in K. pneumoniae isolates and are also frequently associated
with serious nosocomial infections and outbreaks. Prior to the ﬁrst
report of NDM-1 (New Delhi metallo-beta-lactamase) in 2009, the
VIM (Verona integron-encoded MBLs) and IMP (active on
imipenem) types were the common metallo-beta-lactamases
identiﬁed in Enterobacteriaceae.4,5 NDM-1, which originated in
India, has now been isolated in Europe, Asia, North America, and
Australasia, mostly from patients with a history of prior
hospitalization in the Indian subcontinent.6–11 NDM-producers
are of particular concern as they also harbor multiple chromosom-
ally and plasmid-encoded resistance genes resulting in a multi-
drug-resistant phenotype.12,13 The carbapenem-hydrolyzing class
D beta-lactamase (CHDL) OXA-48 was ﬁrst described in a K.
pneumoniae isolate from Turkey in 2004 and is now endemic in
that country.14 CHDL OXA-48 is now endemic in countries around
the Mediterranean and is rapidly spreading into other countries in
Europe.15–19 To date, six OXA-48-like variants have been identiﬁed,
including OXA-181, which has recently been identiﬁed in India in
association with blaNDM-1 and blaVIM-5 genes.
20,21ses. Published by Elsevier Ltd. All rights reserved.
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producing isolates in the Arabian Peninsula and the Middle East.22
Similar reports of Enterobacteriaceae harboring blaNDM-1 have also
emerged from Kuwait and Lebanon.23,24 The recent identiﬁcation
of 11 NDM-1, ﬁve OXA-48, and one NDM-1 plus OXA-181
producers among carbapenem-resistant enterobacterial isolates
from Oman, suggests that carbapenemase producers are now
emerging in the region.25 In Saudi Arabia, unpublished data
suggest that carbapenem-resistant K. pneumoniae are being
isolated in patients with serious nosocomial infections. We present
the ﬁrst report documenting the emergence of NDM-, OXA-48-,
and VIM-producing K. pneumoniae in Saudi Arabia.
2. Methods
The study was carried out in Riyadh, Saudi Arabia, from June to
December 2011. During the study period, all non-duplicate clinicalTable 1
Characterization and antibiotic susceptibility proﬁle of OXA-48-positive isolates
Isolate No. Location of patient Specimen Beta lactamase ge
1 ICU Blood blaCTX-M; blaSHV
2 ICU Blood - 
3 ICU Sputum blaSHV
4 ICU Blood blaCTX-M; blaSHV
5 ICU Urine blaCTX-M
6 ICU Sputum blaCTX-M; blaSHV; b
7 Surgical ward Urine blaCTX-M; blaSHV
8 Medical ward Urine blaSHV
9 ICU Blood blaCTX-M; blaSHV; b
10 Medical ward Sputum blaTEM
11 ICU Suction port - 
12 ICU Rectal blaSHV
13 ICU Rectal blaCTX-M; blaSHV
14 ICU Rectal blaCTX-M; blaSHV
15 ICU Rectal blaCTX-M; blaSHV
16 ICU Blood blaCTX-M; blaTEM
17 ICU Suction port blaTEM
18 ICU Sputum blaCTX-M; blaSHV; b
19 ICU Sputum blaSHV; blaTEM
20 Medical ward Rectal blaCTX-M; blaTEM
21 Surgical ward Urine blaSHV; blaTEM
22 Medical ward Sputum blaCTX-M
23 ICU Rectal blaCTX-M
24 ICU Rectal blaCTX-M
25 Medical ward Rectal blaCTX-M; blaSHV
26 ICU Rectal blaCTX-M; blaSHV
27 ICU Sputum blaCTX-M
28 Surgical ward Wound blaCTX-M; blaSHV; b
29 ICU Sputum blaTEM
30 Surgical ward Urine blaCTX-M; blaSHV; b
31 Surgical ward Rectal blaSHV
32 Surgical ward Urine blaCTX-M
33 ICU Blood blaSHV
34 ICU Wound blaCTX-M; blaSHV
35 ICU Urine blaCTX-M
36 Surgical ward Wound blaCTX-M; blaSHV; b
37 ICU Sputum blaSHV
38 Surgical ward Wound blaSHV
39 ICU Urine blaCTX-M; blaSHV
40 ICU Sputum blaSHV
41 ICU Blood blaTEM
42 ICU Wound blaCTX-M; blaSHV
43 ICU Wound blaSHV; blaTEM
44 ICU Wound blaCTX-M; blaSHV
45 ICU Rectal blaSHV; blaTEM
46 ICU Rectal blaCTX-M
47 ICU Urine blaCTX-M
Total blaCTX-M = 30
blaSHV = 32
blaTEM= 16
GEN, gentamicin; AMK, amikacin; TMP–SMX, trimethoprim–sulfamethoxazole; CIP, c
intermediate resistant; ND, not done.and surveillance isolates of K. pneumoniae obtained from
inpatients that showed reduced sensitivity to carbapenem were
characterized.
2.1. Phenotypic detection of ESBLs and MBLs
ESBL screening was carried out by disk diffusion using
ceftazidime (30 mg) and cefpodoxime (10 mg), in accordance with
the recommendations of the Clinical and Laboratory Standards
Institute (CLSI) guidelines.26 Conﬁrmation of ESBL phenotype was
carried out using the ESBL Etest following the manufacturer’s
guidelines. Determination of the production of carbapenemase
was carried out by modiﬁed Hodge test in accordance with the CLSI
guidelines and Pasteran et al.26,27 Metallo-beta-lactamase (MBL)
production was determined using Etest MBL strips (imipenem/
imipenem + ethylenediaminetetraacetic acid (EDTA)), in accor-
dance with the manufacturer’s directions. A 8-fold reduction innes Antibiotic susceptibility pattern
GEN AMK TMP–SMX CIP COL
R R S R S
R R R R S
R I R R ND
S R R R S
R R S R S
laTEM R R R R S
S R S S S
S R S R S
laTEM R R R R S
R R S R R
R R R R S
R R R R S
R R R S R
R R S R S
R R R R S
S R R S S
R R S R S
laTEM R R R R S
R R R R S
R R R R S
R R R R S
R R R R S
R R R R S
R R R R S
R R R R S
S R S S S
R I S R S
laTEM S R R R S
R R R R S
laTEM S S R R S
S R R I S
R R R R S
S R R R S
R R S R R
R R R R S
laTEM S R R R S
S R R R S
R R S R S
R S S R S
R R R R S
R R R R S
R R R R S
S R S R S
S R R R S
S R R S S
S R R R S
R R R S S
R = 32 R = 45 R = 33 R = 41 R = 3
iproﬂoxacin; COL, colistin; ICU, intensive care unit; R, resistant; S, sensitive; I,
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presence of EDTA, or a phantom zone, was taken as indicative of
MBL production.
2.2. Detection of resistance genes
PCR ampliﬁcation was carried out for the detection of blaESBL
(blaCTX-M, blaTEM, blaSHV) with primers described previously.
28 PCR
ampliﬁcation was carried out for the detection of ESBL genes
(blaCTX-M, blaTEM, blaSHV) and carbapenemase genes (blaKPC, blaVIM,
blaIMP, blaSIM, blaGIM, blaSPM, blaNDM, and blaOXA-48) using previously
described primers and methodology.29–32 The subgroups of CTX-M
were determined by PCR using the procedures of Woodford et al.33
2.3. Antibiotic susceptibility
MICs of imipenem and meropenem were determined by Etest,
as described previously, in accordance with CLSI guidelines.26
Sensitivity to a panel of antibiotics including amikacin, gentamicin,
trimethoprim–sulfamethoxazole, and colistin, was assessed.
3. Results
A total of 60 K. pneumoniae isolates were identiﬁed and studied.
The majority of these were from patients in the intensive care unit
(ICU; n = 45), while others were from patients on the surgical and
medical wards. Specimen sources were blood (n = 9), rectal swabs
(n = 16), sputum (n = 13), urine (n = 11), wound (n = 9), and suction
swab (n = 2). All isolates were conﬁrmed to be carbapenemase-
producers by modiﬁed Hodge test. The carbapenemase gene
blaOXA-48 was detected in 47 (78%) isolates, blaNDM-1 in 12 (20%),
and blaVIM in one (1.6%). No isolate harbored a combination of
blaNDM-1 and blaOXA-48. None of the isolates harbored either blaKPC
or blaIMP. Thirty-seven isolates were positive for blaCTX-M and all
belonged to CTX-M group 1. Twenty-nine were positive for both
blaCTX-M and blaOXA-48. The blaTEM and blaSHV genes were detected
in 17 and 39 isolates, respectively. All isolates were resistant to
imipenem and meropenem. The distribution, characterization, and
antibiotic susceptibility proﬁle of blaOXA-48-positive and blaNDM-1-
positive isolates are shown in Tables 1 and 2, respectively. There
was a high degree of resistance to amikacin, gentamicin,
ciproﬂoxacin, and trimethoprim–sulfamethoxazole. Three isolates
with resistance to colistin were identiﬁed and they were positive
for blaOXA-48 (Table 1).Table 2
Characterization and antibiotic susceptibility proﬁle of NDM-1-positive isolates
Isolate No. Location of patient Specimen Other resistance genes
1 ICU Sputum blaSHV
2 ICU Urine blaTEM
3 Surgical ward Rectal blaCTX-M
4 ICU Wound blaTEM
5 ICU Rectal blaCTX-M; blaSHV
6 ICU Blood blaCTX-M; blaSHV
7 ICU Wound blaCTX-M; blaSHV
8 ICU Blood blaCTX-M
9 ICU Rectal blaCTX-M; blaSHV
10 ICU Sputum blaCTX-M; blaSHV
11 ICU Sputum - 
12 Surgical ward Urine blaCTX-M; blaSHV
Total blaCTX-M= 8
blaSHV= 7
blaTEM= 2
GEN, gentamicin; AMK, amikacin; TMP–SMX, trimethoprim–sulfamethoxazole; CIP, cip4. Discussion
The dissemination of K. pneumoniae isolates harboring carba-
penemase resistance genes, in particular blaOXA-48 and blaNDM-1,
continues unabated, and reports describing these isolates are
emerging from different parts of the world. In the Arabian Gulf
region, NDM-1, OXA-48, and OXA-181 carbapenemase-producing
Enterobacteriaceae have been reported in Oman.22 In addition, the
detection of blaNDM-1-positive K. pneumoniae in two patients at a
tertiary care teaching hospital in Kuwait has been reported.24 A
PubMed search did not identify any published report describing
the occurrence and distribution of blaOXA-48- and blaNDM-1-
producing Enterobacteriaceae in Saudi Arabia. The data presented
here, based on a 6-month survey, provide the ﬁrst insight into the
widespread occurrence of K. pneumoniae isolates harboring blaOXA-
48 and blaNDM-1 among patients in healthcare facilities in Riyadh,
Saudi Arabia. The majority of the isolates were from clinical
specimens and were from patients in the ICU. This indicates that in
this setting K. pneumoniae isolates producing carbapenemases are
associated with nosocomial infections in seriously ill patients.
Although India and Pakistan are considered to be the main
reservoir for NDM-producing isolates, it has been suggested that
the Middle East region might be a secondary reservoir for the
spread of blaNDM-1 isolates as there is a high frequency of
population movement between Saudi Arabia and the Indian
subcontinent.34,35 We speculate that a similar population move-
ment with Turkey, where K. pneumoniae with blaOXA-48 is endemic,
might explain the high occurrence of isolates with this resistance
gene in our setting, although the absence of data on travel history
for the patients precludes any ﬁrm conclusions being drawn. The
emergence of blaNDM-1 and blaOXA-48 isolates in our setting has
signiﬁcant implications as it is not uncommon for patients from
Saudi Arabia to travel abroad for further healthcare services,
raising the possibility of dissemination of these isolates into other
countries. Indeed, such dissemination via health tourism was
demonstrated in a recently published report of the ﬁrst two clinical
cases of OXA-48-type carbapenemase-producing Enterobacteria-
ceae in the USA, in which one of the patients had a history of recent
hospitalization in Saudi Arabia.36
Only one isolate was found with blaVIM and no KPC isolates were
identiﬁed, indicating that these are not major sources of
carbapenemases in our setting. The plasmid-encoded KPC enzyme
was ﬁrst identiﬁed in a K. pneumoniae isolate from North Carolina,
USA.37 Since 2001, these isolates have spread across the USA, with
reports of KPC-producers across 38 states.37,38 Although present Antibiotic susceptibility pattern
GEN AMK TMP–SMX CIP COL
R R R R S
R R R R S
R R S R S
S R S R S
R R R R S
R R R R S
R R R R S
R R R R S
R S R R S
R R R R S
R R R R S
R R R R S
R = 11 R = 11 R = 10 R = 12 R = 0
roﬂoxacin; COL, colistin; ICU, intensive care unit; R, resistant; S, sensitive.
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Europe, facilitated mostly by clonal dissemination, to the best of
our knowledge there is no published report of blaKPC-positive
isolates from the Arabian Peninsula.39
The antibiotic susceptibility proﬁle of our isolates is in keeping
with the reported multidrug-resistant phenotype associated with
isolates harboring blaNDM-1 and blaOXA-48. The weak hydrolytic
effect on carbapenems exhibited by OXA-48-producers is not
affected by EDTA or clavulanic acid, but is enhanced if there is
associated ESBL activity and outer membrane permeability
defects.14 Thus the co-existence of beta-lactamase genes such as
demonstrated in our isolates, enhances the antimicrobial resis-
tance, particularly in blaOXA-48 isolates. As colistin remains one of
the last drugs of choice for the treatment of infections caused by
carbapenemase-producing Enterobacteriaceae, the ﬁnding of car-
bapenemase-producers with resistance to this, as reported herein,
is of major concern. Although this report has documented the
widespread occurrence of these isolates in our setting, a major
limitation is the absence of detailed epidemiological data and
molecular characterization. Hence, we suggest that there is an
urgent need for further studies to clearly map out the epidemiolo-
gy and to conduct molecular characterization of carbapenemase-
producing isolates in Saudi Arabia. Healthcare facilities in the
country need to be aware of the emergence of these multidrug-
resistant isolates, as these are of signiﬁcant public health concern
both in the hospital and community setting. A process of enhanced
surveillance for the detection of these multidrug-resistant patho-
gens is urgently advocated so that patients can be identiﬁed
quickly and appropriate infection control measures instituted to
stem further dissemination.
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